Melanoma breakthrough paves way for personalised treatment for all cancer patients

Melanoma breakthrough paves way for personalised treatment for all cancer patients

14 February 2019

Australian researchers have for the first time identified specific cells and receptors in the immune system which predict how a patient will respond to treatment with immunotherapies, potentially paving the way for the development of personalised therapy for all cancer patients.

The groundbreaking research, published in Cancer Cell by a team of researchers from Melanoma Institute Australia (MIA), identifies markers of response and resistance in metastatic melanoma patients.

Co-Medical Director of Melanoma Institute Australia, Professor Georgina Long, said the findings have the potential to revolutionalise how treatment is delivered for all cancer patients.

‘Immunotherapy is the new frontier of melanoma treatment, and whilst it has had astounding results for patients who respond, there has been a subset of patients who are resistant to the treatment,’ Professor Long said.

‘Being able to identify the immune markers of response takes out the guess work, and allows us to be proactive in providing the right drug treatment for the right patients. This has the potential to revolutionise how all cancers are treated around the world.’

The Melanoma Institute Australia team, led by PhD student Tuba Nur Gide and postdoctoral scientists Camelia Quek and James Wilmott, performed immune profiling on 158 tumour biopsies from melanoma patients treated with anti-PD-1 monotherapy or combined anti-PD-1 and anti-CTLA-4 therapy.

They found that genes involving immune memory and activation were higher in responders to immunotherapy, whereas non-responders showed higher levels of genes related to tumour adaptation and cancer cell survival.

Examining more closely the immune cells in the tumours of responders, a specific sub-type of T-cell was found to be correlated with response and survival. Patients with this immune cell had significant shrinkage of their tumours, and longer progression-free survival .

Non-responding patients were found to lie in two distinct groups – one that can possibly benefit from other available treatment combinations, and another that requires more research into novel treatment strategies. The first group were seen to have several other potential therapeutic targets, possibly leading to the development of individualised immunotherapy for selected patients.

‘In addition to knowing up front which patients are likely to respond to current immunotherapy treatments, these findings will also enable us to focus research efforts on developing new therapies targeting the biological markers identified in current non-responders,’ Professor Long  added.

‘The result will be personalised immunotherapy treatment for all patients, based not on their type of cancer, but based on their tumour’s unique biology.’

The study is the largest dataset of patients treated with anti-PD-1-based therapies to be published to date, and this data is now available for use by researchers and clinicians internationally.

Australasian Melanoma Conference AMC2021
19 Nov - 20 Feb 2021

Australasian Melanoma Conference AMC2021

The 2021 Australasian Melanoma Conference (AMC2021) will held in Sydney, Australia.

Sharing our knowledge of melanoma on the global stage
15 Apr 2021

Sharing our knowledge of melanoma on the global stage

As leaders in the field of melanoma, clinicians and researchers from MIA will be sharing their knowledge at the virtual 10th World Congress of Melanoma. 

Tags: melanoma
Community Fundraising Wrap Up Jan-Mar 2021
15 Apr 2021

Community Fundraising Wrap Up Jan-Mar 2021

The easing of COVID restrictions has meant the return of community events, and we recognise the generous support of our community fundraisers.

Tags: melanoma
Melanoma patients and their families urged to speak up and put national spotlight on melanoma.
15 Apr 2021

Melanoma patients and their families urged to speak up and put national spotlight on melanoma.

Melanoma patients and their carers are being urged to participate in a ground-breaking survey which will shape the future of melanoma treatment, research, support and funding in Australia.

Tags: melanoma
Support for Melanoma March has come from everywhere
12 Apr 2021

Support for Melanoma March has come from everywhere

We have been buoyed by the wonderful support for our Melanoma March campaign, and our mission to cover Australia in footprints continues into April!

An inspiring WA Melanoma Community Forum
26 Mar 2021

An inspiring WA Melanoma Community Forum

There was a wonderful feeling of community support amongst the melanoma patients, families and friends at the WA Melanoma Community Form. 

Tags: melanoma
Family of 8-year-old with melanoma calls on all Australians to step up to help save lives
26 Mar 2021

Family of 8-year-old with melanoma calls on all Australians to step up to help save lives

The Price family has decided to share their story to inspire Australians to support research into new melanoma treatments.

Tags: melanoma
Rethinking skin surveillance for high-risk melanoma patients
18 Mar 2021

Rethinking skin surveillance for high-risk melanoma patients

New research has provided evidence in favour of a structured skin surveillance program for high-risk melanoma patients.

Tags: melanoma
Australia's oldest melanoma survivor steps up to save lives on his 105th birthday
11 Mar 2021

Australia's oldest melanoma survivor steps up to save lives on his 105th birthday

Melanoma research saved Bert's life at 101 and now he wants to give back. 

Tags: melanoma
Predicting disease spread in thin melanoma
05 Mar 2021

Predicting disease spread in thin melanoma

A new MIA online risk calculator for clinicians can determine the likelihood of thin melanoma spreading.   

Tags: melanoma
Exploring our own clinical questions through MIA's new trials initiative
04 Mar 2021

Exploring our own clinical questions through MIA's new trials initiative

MIA has recently established a new division of our Clinical Trials Program which co-ordinates and manages investigator-led multi-centre trials. 

Tags: melanoma
Young researchers awarded Fellowships to pursue innovative treatments for melanoma
04 Mar 2021

Young researchers awarded Fellowships to pursue innovative treatments for melanoma

Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.

Tags: melanoma
Young researchers receive boost to develop innovative treatment for melanoma
04 Mar 2021

Young researchers receive boost to develop innovative treatment for melanoma

Two young researchers from MIA and The University of Sydney awarded Cancer Institute NSW fellowships.

Tags: melanoma
Launch of Melanoma March 2021
01 Mar 2021

Launch of Melanoma March 2021

Aussies urged to leave their footprint on melanoma as efforts step up to save lives from the disease.

Tags: melanoma
Olivia Vivian announced as MIA ambassador
12 Feb 2021

Olivia Vivian announced as MIA ambassador

Olivia is using her Ninja star power to shine a spotlight on melanoma prevention - in memory of her dad. 

Tags: melanoma
Melanoma breakthrough - neoadjuvant treatment saving lives.
09 Feb 2021

Melanoma breakthrough - neoadjuvant treatment saving lives.

Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.

Tags: melanoma
Melanoma breakthrough - neoadjuvant therapy saving lives.
09 Feb 2021

Melanoma breakthrough - neoadjuvant therapy saving lives.

Drug treatment before surgery, known as neoadjuvant therapy, is being hailed as one of the biggest breakthroughs in melanoma treatment since the advent of immunotherapy.

Tags: melanoma
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
04 Feb 2021

Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?

New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.

Tags: melanoma
Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?
04 Feb 2021

Are cancer patients on immunotherapy at a greater risk of severe COVID-19 infection?

New research, led by MIA, has revealed that cancer patients treated with immunotherapy are not at a higher risk of developing severe COVID-19 infection compared to other cancer patients.

Tags: melanoma
A message to all Australians from melanoma patient Stuart Taylor
16 Dec 2020

A message to all Australians from melanoma patient Stuart Taylor

Stuart has advanced melanoma which is not responding to treatment. He has shared his story on ABC's 7:30 in the hope that others can escape the same fate. 

Tags: melanoma